RECRUITING

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.

Official Title

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Quick Facts

Study Start:2024-05-08
Study Completion:2026-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06812429

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age: ≥18
  2. 2. Patient has no prior history or current use of Sodium-Glucose Co-transporter 2 Inhibitors.
  3. 3. Women who are surgically sterilized, amenorrheic for a year, on long-term contraceptives like intrauterine devices, Implantable, and injectable contraceptives.
  4. 4. Willing and able to complete the outcome assessments.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Amen Bekele Zelleke
CONTACT
7207612871
a.zelleke@wustl.edu
Stephanie Stilinovic
CONTACT
314-200-5382

Study Locations (Sites)

Washington University
Saint Louis, Missouri, 63110
United States

Collaborators and Investigators

Sponsor: Washington University School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-08
Study Completion Date2026-06

Study Record Updates

Study Start Date2024-05-08
Study Completion Date2026-06

Terms related to this study

Keywords Provided by Researchers

  • SGLT2 inhibitors, Dapagliflozin, Inflammation, Healthy Individuals

Additional Relevant MeSH Terms

  • Inflammation